Cancer Letters
Volume 253, Issue 1 , Pages 131-137 , 8 August 2007

Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines

Received 20 November 2006 ,Revised 23 January 2007 ,Accepted 23 January 2007.

References 

  1. Maier H, Dietz A, Geelke U, Heller WD, Weidauer H. Tobacco and alcohol and the risk of head and neck cancer. Clin. Invest. 1992;70:320–327
  2. Takes RP, Baatenburg de Jong RJ, Schuuring E, Hermans J, Vis AA, Litvinov SV, et al. Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch. Otolaryngol. Head Neck Surg. 1997;123:412–419
  3. Friedberg E, Walker G, Siede W, Wood R, Schultz R, Ellenberger T. DNA Repair and Mutagenesis. Washington, D.C.: ASM Press; 2006;
  4. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson S, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 2003;9:568–574
  5. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther. 2006;5:952–961
  6. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-C resistance and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 2001;61:4842–4850
  7. McHugh PJ, Sarkar S. DNA interstrand cross-link repair in the cell cycle: A critical role for polymerase zeta in G(1) phase. Cell Cycle. 2006;5:
  8. Albertella MR, Green CM, Lehmann AR, O’Connor MJ. A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res. 2005;65:9799–9806
  9. Mirchandani KD, D’Andrea AD. The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair. Exp. Cell Res. 2006;312:2647–2653
  10. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell. 2001;7:249–262
  11. Vandenberg CJ, Gergely F, Ong CY, Pace P, Mallery DL, Hiom K, et al. J. BRCA1-independent ubiquitination of FANCD2. Mol. Cell. 2003;12:247–254
  12. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, et al. p53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck. 2003;25:654–661
  13. O’Hagan HM, Ljungman M. Phosphorylation and nuclear accumulation are distinct events contributing to the activation of p53. Mutat. Res. 2004;546:7–15
  14. Chung DH, Zhang FF, Chen F, McLaughlin WP, Ljungman M. Butyrate attenuates Bcl-XL expression in human fibroblasts and acts in synergy with ionizing radiation to induce apoptosis. Radiat. Res. 1998;149:187–194
  15. Ljungman M, Zhang F. Blockage of RNA polymerase as a possible trigger for UV light-induced apoptosis. Oncogene. 1996;13:823–831
  16. Andreassen PR, D’Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev. 2004;18:1958–1963
  17. Snyder ER, Ricker JL, Chen Z, Waes CV. Variation in cisplatinum sensitivity is not associated with Fanconi anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines. Cancer Lett. 2006;
  18. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene. 2004;23:1000–1004

PII: S0304-3835(07)00036-5

doi: 10.1016/j.canlet.2007.01.017

Cancer Letters
Volume 253, Issue 1 , Pages 131-137 , 8 August 2007

Article Tools

* Image Usage & Resolution